SYNTHESIS AND DOPAMINE AGONIST PROPERTIES OF (+/-)-TRANS-3,4,4A,10B-TETRAHYDRO-4-PROPYL-2H,5H-[1]BENZOPYRANO[4,3-B]-1,4-OXAZIN-9-OL AND ITS ENANTIOMERS

被引:56
|
作者
DEWALD, HA
HEFFNER, TG
JAEN, JC
LUSTGARTEN, DM
MCPHAIL, AT
MELTZER, LT
PUGSLEY, TA
WISE, LD
机构
[1] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CHEM,ANN ARBOR,MI 48105
[2] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT PHARMACOL,ANN ARBOR,MI 48105
[3] DUKE UNIV,PAUL M GROSS CHEM LAB,DEPT CHEM,DURHAM,NC 27706
关键词
D O I
10.1021/jm00163a068
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The dopamine agonist profile of (±)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-6]-1,4-oxazm-9-ol (16a) and its enantiomers (16b-c) was examined. Racemic 16a exhibited moderate affinity for the dopamine (DA) D2receptor labeled with the DA antagonist ligand [3H]haloperidol and moderate in vivo activity; it attenuated γ-butyrolactone-stimulated DA synthesis, decreased DA neuronal firing of substantia nigra DA neurons, and inhibited exploratory locomotor activity in rats, a profile consistent with a DA autoreceptor agonist mechanism of action. The (+)-enantiomer 16b possessed greater DA receptor affinity with the agonist ligand [3H]-Ar-propylnorapomorphine than with the antagonist ligand. In rats it potently inhibited DA synthesis and neuronal firing and also inhibited exploratory locomotion. The (-)-enantiomer, on the other hand, did not have significant activity in any of these tests. This profile indicates that like many other rigid DA agonists, the dopaminergic activity resides in one enantiomer, in this case the (+)-enantiomer 16b. On the basis of single-crystal X-ray analysis of a key intermediate, the absolute configuration of 16b was found to be 4aR, 10bR. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:445 / 450
页数:6
相关论文
共 50 条
  • [1] Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907)
    van Vliet, LA
    Rodenhuis, N
    Dijkstra, D
    Wikström, H
    Pugsley, TA
    Serpa, KA
    Meltzer, LT
    Heffner, TG
    Wise, LD
    Lajiness, ME
    Huff, RM
    Svensson, K
    Sundell, S
    Lundmark, M
    JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) : 2871 - 2882
  • [2] The D2/D3 Agonist PD128907 (R-(+)-trans-3,4a,10b-Tetrahydro-4-Propyl-2H,5H-[1]Benzopyrano[4,3-b]-1,4-Oxazin-9-ol) Inhibits Stimulated Pyloric Relaxation and Spontaneous Gastric Emptying
    Kashyap, Purna
    Micci, Maria-Adelaide
    Pasricha, Sarina
    Pasricha, Pankaj Jay
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (01) : 57 - 62
  • [3] The D2/D3 Agonist PD128907 (R-(+)-trans-3,4a,10b-Tetrahydro-4-Propyl-2H,5H-[1]Benzopyrano[4,3-b]-1,4-Oxazin-9-ol) Inhibits Stimulated Pyloric Relaxation and Spontaneous Gastric Emptying
    Purna Kashyap
    Maria-Adelaide Micci
    Sarina Pasricha
    Pankaj Jay Pasricha
    Digestive Diseases and Sciences, 2009, 54 : 57 - 62
  • [4] Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol[(+)-PD 128,907]
    Witkin, JM
    Dijkstra, D
    Levant, B
    Akunne, HC
    Zapata, A
    Peters, S
    Shannon, HE
    Gasior, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03): : 957 - 964
  • [5] SYNTHESIS AND DOPAMINERGIC ACTIVITY OF TRANNS-3,4,4A,10B-TETRAHYDRO-2H,5H-[1]BENZOPYRANO[4,3B][1,4]OXAZINES
    DIJKSTRA, D
    MULDER, TBA
    ROLLEMA, H
    TEPPER, PG
    VANDERWEIDE, J
    HORN, AS
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1986, 8 (06) : 336 - 336
  • [6] SYNTHESIS AND PHARMACOLOGY OF TRANS-4-NORMAL-PROPYL-3,4,4A,10B-TETRAHYDRO-2H,5H-1-BENZOPYRANO[4,3-B]-1,4-OXAZIN-7-OLS AND 9-OLS - THE SIGNIFICANCE OF NITROGEN PKA VALUES FOR CENTRAL DOPAMINE RECEPTOR ACTIVATION
    DIJKSTRA, D
    MULDER, TBA
    ROLLEMA, H
    TEPPER, PG
    VANDERWEIDE, J
    HORN, AS
    JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (11) : 2178 - 2182
  • [7] The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans3,4a, 10b-tetrahydro-4-propyl-2H, 5H-[1] benzopyrano[4,3-b]1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice:: Further evidence for the involvement of D3 receptors
    Witkin, J. M.
    Levant, B.
    Zapata, A.
    Kaminski, R.
    Gasior, M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (03): : 930 - 938
  • [8] A SENSITIVE GAS-CHROMATOGRAPHIC MASS-SPECTROMETRIC ASSAY FOR A NOVEL DOPAMINE AGONIST (+)-TRANS-3,4,4A,5,6,10B-HEXAHYDRO-4-PROPYL-2H-NAPHTH(1,2-B)(1,4)OXAZIN-9-OL IN HUMAN-PLASMA
    MUSSON, DG
    TOBIAS, RJ
    MAGLIETTO, BK
    RAMJIT, HG
    BAYNE, WF
    BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1988, 17 (04): : 293 - 298
  • [9] SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 3,4,4A,5,6,10B-HEXAHYDRO-2-FLUORO-4-PROPYL-2H-NAPHTH[1,2-B]-1,4-OXAZIN-9-OL (2-FLUORO-PHNO)
    MINASKANIAN, G
    PAFF, ML
    PECK, JV
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 204 : 79 - MEDI
  • [10] 3,4,4A-ALPHA,10A-ALPHA-TETRAHYDRO-7-NITRO-2H,5H-[1]BENZOPYRANO[2,3-B]PYRAN
    JONES, PG
    KENNARD, O
    KIRBY, AJ
    MARTIN, RJ
    ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1979, 35 (JAN): : 242 - 244